Research Paper Volume 13, Issue 18 pp 22588—22610

GPR43 regulation of mitochondrial damage to alleviate inflammatory reaction in sepsis

Nox1/EBP50/p47phox is involved in the activation of NLRP3 inflammasome by GRP43 gene in sepsis model. EBP50 and p47phox sequence structures highlighting the PDZ domains of EBP50 and the potential PDZ-binding motif on p47phox, streptavidin regulated anti-p47phox or anti-EBP50 antibodies on RAW264.7 cell (A); Anti-FLAG antibody with anti-p47phox or anti-FLAG antibodies on lysates (B); P47phox and EBP50 expression in vitro model using confocal (C); Outline of p47phox sequence structures highlighting the mutation (in red) of C-terminal PDZ binding motif on p47phox (D); NOX-1 and p47phox sequence structures highlighting the PDZ domains of NOX-1 and the potential PDZ-binding motif on p47phox (E); Anti-FLAG antibody with anti- NOX-1 or anti-FLAG antibodies on lysates (F); NOX-1 and EBP50 expression in vitro model using confocal (G); Nox1, EBP50 and p47phox protein expressions in macrophage by down-regulation of GPR43 and LPS+ATP+GPR43 agonist (H, I). Control, control group; LPS+ATP, macrophage by treated with LPS+ATP; L-4-CMTB, 10 μM of 4-CMTB; M-4-CMTB, 20 μM of 4-CMTB; H-4-CMTB, 40 μM of 4-CMTB. ##p

Figure 6. Nox1/EBP50/p47phox is involved in the activation of NLRP3 inflammasome by GRP43 gene in sepsis model. EBP50 and p47phox sequence structures highlighting the PDZ domains of EBP50 and the potential PDZ-binding motif on p47phox, streptavidin regulated anti-p47phox or anti-EBP50 antibodies on RAW264.7 cell (A); Anti-FLAG antibody with anti-p47phox or anti-FLAG antibodies on lysates (B); P47phox and EBP50 expression in vitro model using confocal (C); Outline of p47phox sequence structures highlighting the mutation (in red) of C-terminal PDZ binding motif on p47phox (D); NOX-1 and p47phox sequence structures highlighting the PDZ domains of NOX-1 and the potential PDZ-binding motif on p47phox (E); Anti-FLAG antibody with anti- NOX-1 or anti-FLAG antibodies on lysates (F); NOX-1 and EBP50 expression in vitro model using confocal (G); Nox1, EBP50 and p47phox protein expressions in macrophage by down-regulation of GPR43 and LPS+ATP+GPR43 agonist (H, I). Control, control group; LPS+ATP, macrophage by treated with LPS+ATP; L-4-CMTB, 10 μM of 4-CMTB; M-4-CMTB, 20 μM of 4-CMTB; H-4-CMTB, 40 μM of 4-CMTB. ##p<0.01 compared with control group; **p<0.01 compared with LPS+ATP.